News

The Manila Times5d
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Daré Bioscience stockholders as of close of business on the April 17, 2025 record date for the Annual Meeting, or their legal ...
The Manila Times13d
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré's DARE to PLAY Sildenafil Cream
Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making ...
KTLA10mon
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
“In addition to the continued commercialization by our collaborator Organon of XACIATO™ (clindamycin phosphate) vaginal gel 2%, the first FDA-approved product to emerge from our portfolio and ...
elEconomista11mon
Organon tantea a Almirall para que le fabrique parte de sus medicamentos
Organon, compañía farmacéutica nacida de ... Ese mismo año, también adquirió Xaciato de Daré Bioscience, un gel para la vaginosis bacteriana.
Business Insider1y
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and ...
Yahoo Finance1y
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
XACIATO™ is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. In 2022, Daré entered into a license agreement ...